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Abstract Chemokines and their receptors are implicated in
formation of colorectal cancer metastases. Especially
CXCR4 is an important factor, determining migration,
invasiveness, metastasis and proliferation of colorectal
cancer cells. Object of this study was to determine
expression of CXCR4 in tumor tissue of colorectal cancer
patients and associate CXCR4 expression levels to clinico-
pathological parameters. Levels of CXCR4 expression of a
random cohort of patients, who underwent primary curative
resection of a colorectal carcinoma, were retrospectively
determined by quantitative real-time RT-PCR and semi-
quantitative analyses of immunohistochemical stained
paraffin sections. Expression levels were associated to
clinicopathological parameters. Using RT-PCR we found
that a high expression of CXCR4 in the primary tumor was
an independent prognostic factor for a poor disease free
survival (p=0.03, HR: 2.0, CI=1.1–3.7). Immunohisto-
chemical staining showed that nuclear distribution of
CXCR4 in the tumor cells was inversely associated with
disease free and overall survival (p=0.04, HR: 2.6, CI=
1.0–6.2), while expression in the cytoplasm was not
associated with prognosis. In conclusion, our study showed
that a high expression of nuclear localized CXCR4 in tumor





More than 100 years after postulation of the “seed and soil”
theory, the precise mechanisms determining the directional
migration and invasion of diminished cancer cells into
specific organs remain to be established [1, 2]. Recent
studies increasingly show that chemokines and their
receptors are an important factor in this process of organ
selective metastasis [3].
Chemokines are small signaling cytokines that act as
chemoattractants through interaction with G-protein-
coupled, seven transmembrane domain receptors [4, 5].
They are the major regulators of cell trafficking and
adhesion. Specific chemokines are produced and released
by target organs that attract tumor cells with specific
corresponding receptors, resulting in site/organ specific
cancer cell migration and formation of metastasis. This
migration signaling mechanism is supported by studies in
cancer models, demonstrating that malignant cells can
target specific organs or tissues by selected chemokine
receptor-ligand interaction [6–10]. Accordingly, neutraliza-
tion of CXCL12-CXCR4 interaction leads to a marked
inhibition of metastasis in tumor animal models [6, 11, 12].
Muller et al. were the first to implicate a key role for
CXCR4-CXCL12 in the organ specific metastasis of breast
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the involvement of CXCR4-CXCL12 in promoting the
metastatic homing of different types of tumor cells,
including colorectal cancer [10, 13–16]. CXCR4 is
expressed in intestinal cells and over-expressed in colorec-
tal tumor cells [16–18]. It is activated upon binding with its
ligand CXCL12 also known as stromal cell-derived factor
(SDF-1), triggering cell adhesion, directional migration and
proliferation of tumor cells [6]. CXCL12 is normally
produced by stromal cells of lymph nodes, lung, liver and
bone marrow. These are the most frequent sites for
colorectal cancer metastases [19].
At the moment only the TNM classification is used to
stage patients with colorectal cancer. New prognostic
biomarkers are required to improve staging of colorectal
cancer patients and thereby resulting in better selection of
patients that might benefit from (adjuvant) therapy. Many
studies have demonstrated an important association be-
tween CXCR4 expression and clinical prognosis of patients
with various types of cancer [3, 13, 14, 20–23]. In our
study, we retrospectively determined the level of expression
and cellular distribution of CXCR4 in association with
clinical, pathological and prognostic parameters in tumor
tissue of a random selected cohort of colorectal cancer
patients, using RT-PCR and immunohistochemical techni-
ques. This study focuses whether CXCR4 might function as
a biomarker to improve the current staging of colorectal
cancer patients.
Material and Methods
Tumor Specimens for RT-PCR
RNA from snap-frozen tumor samples, containing at least
60% tumor cells as determined by a pathologist (HM), of
70 curatively operated colorectal cancer patients was
isolated using RNeasy columns (Qiagen, USA). All patient
materials were obtained with approval of local medical
ethic committee. Patients were operated between 1990 and
2001, at the time of censoring 41 (59%) had died of whom
22 (54%) died from their disease, and 29 patients were still
alive; four of them were alive with recurrence of the tumor.
Mean follow up was 99 months (range 50–172 months).
Patients with stage I/II (n=47) and stage III (n=23)
colorectal cancer (as defined by the American Joint
committee on Cancer and Union Internationale Contre le
Cancer-criteria) were selected for this study.
RT-PCR of CXCR4 in a Patient Cohort
PCR primers for the detection of CXCR4 and the house-
keeping genes (heterogeneous nuclear ribonucleoprotein M
(HNRPM) and TATA box binding protein (TBP) were
designed in PRIMER Express (Applied Biosystems, USA)
and span at least one exon-exon boundary. The primers
used were: HNRPM, 5’-GAGGCCATGCTCCTGGG-3’,
5’-TTTAGCATCTTCCATGTGAAATCG-3’,T B P ,5 ’-
CACGAACCACGGCACTGAT-3’,5 ’-TTTTCTTGCTGC
CAGTCTGGAC-3’ and CXCR4 5’-TTCTACCCCAAT
GACTTGTG-3’-5’-ATGTAGTAAGGCAGCCAACA-3’.
RT-PCR reactions were performed on an ABI Prism 7900ht
(Applied Biosystems) using the SybrGreen RT-PCR core-
kit (Eurogentec, Belgium). Cycle conditions were 10 min at
95°C followed by 40 cycles of 10 s at 95°C and 1 min at
60°C. Cycle threshold extraction was performed using the
SDS software (version 2.2.2, Applied Biosystems). For all
PCR reactions, a standard curve was generated using a five-
step, five-fold dilution of pooled cDNA from the HCT81
colorectal cancer cell line. Relative concentrations of
mRNA for each gene were calculated from the standard
curve. After RT-PCR, dissociation curves were made to
check the quality of the reaction. Reactions with more than
one peak in the dissociation curve were discarded. For
normalization, the expression values for each gene were
divided by the normalization factor of the gene (the average
of the two house keeping genes).
Immunohistochemistry of CXCR4 in a Patient Cohort
A tissue microarray (TMA) was constructed from formalin-
fixed, paraffin-embedded tissues from 58 curatively oper-
ated colorectal cancer patients as described previously [24].
Standard three-step, indirect immunohistochemistry was
performed on 4-μm tissue sections transferred to glass
slides using a tape-transfer system (Instrumedics, USA),
including citrate antigen retrieval and blockage of endog-
enous peroxidase. Sections were overnight incubated with
the primary antibody CXCR4 (Mouse-anti-Human CXCR4
IgG2B, clone MAB172, R&D Systems, USA). Secondary
reagent used was biotinylated rabbit anti-mouse IgG
antibodies (DAKO Cytomation, Denmark) and biotiny-
lated-peroxidase streptavidin complex (SABC; DAKO
Cytomation, Denmark). Microscopic analysis was
assessed by two independent observers (F.M.S. and C.J.
K.) in a double-blinded manner. Three different punches
per patient were scored. Cytoplasmic and nuclear
intensity of CXCR4 staining were separately scored in
two categories: low (0) or strong (1). Since the envelope
of all nuclei of all tumors was stained, nuclear intensity
was determined on the degree of staining of the
nucleoplasm. Where discrepancies arose between the
staining of scores from the same tumor, an average of
the scores was taken, with confirmation by two observers
using a double-headed microscope with a consensus
decision taken in all cases. Tissue stromal cells, normal
2 F.M. Speetjens et al.epithelium or lymph follicles served as positive internal
controls to ascertain the quality of the staining. To
distinct microsatellite instable (MSI) from microsatellite
stable (MSS) tumors, the TMA was stained for mismatch
repair proteins MLH1 and PMS2, as previously described
[25]. MLH1 and PMS2 are deficient in sporadic MSI
tumors. Therefore, the expression of these proteins was
used to differentiate MSI and MSS rectal cancers. Tissue
stromal cells, normal epithelium or lymph follicles served
as positive internal controls when analyzing MLH1, PMS2
expression. The expression of MLH1 and PMS2 was scored
positive if tumor cells showed expression, and negative if
tumor cells showed no expression of either MLH1 or
PMS2, provided that tissue stromal cells did show
expression, indicating MSS and MSI tumors, respectively
[26].
Statistical Analysis
All analyses were performed with SPSS statistical software
(version 12.0 for Windows, SPSS Inc, Chicago, USA).
Mann-Whitney U test (M-W) was used to compare
variables. Kaplan-Meier analyses were performed to ana-
lyze patient survival. The entry date for the survival
analyses was the time of surgery of the primary tumor.
Events for disease free survival and overall survival were
defined as follows: from time of surgery to time of disease
relapse or death by any cause (for disease free survival) and
time of death by any cause (for overall survival),
respectively. Patients were first separately analyzed in
univariate analysis in addition, variables with a P value of
<0.10 in the univariate analyses were subjected to a
multivariate analysis. Cox’ regression analyses were used
to calculate hazard ratios (HR) with 95% confidence
intervals (CI).
Results
Low Levels of CXCR4 RNA Expression Predict Good
Prognosis
The RNA level of CXCR4 was determined in primary
tumor tissue of a cohort of 70 colorectal cancer patients
using quantitative RT-PCR and linked to clinical follow-up
data. The impact of high versus low expression of CXCR4
was assessed using the 50
th percentile cut-off point as
previously defined [10, 14]. The characteristics of the
cohort colorectal cancer patients, included in this study are
summarized in Table 1. To evaluate whether CXCR4 and
clinicopathological features were associated, the level of
CXCR4 was correlated to each feature. CXCR4 expression
was not associated with any of the clinicopathological
variables (Table 1). Univariate cox regression analyses were
performed to identify prognostic factors for disease free
survival and overall survival (Table 1). Advanced patient
age (p=0.006; p=0.005), TNM stage (p<0.001; p<0.001),
and high CXCR4 expression (p=0.006; p=0.01) proved to
be significant predictors for poor disease free and overall
survival respectively, using univariate analyses (Table 1).
The Kaplan-Meier curve for disease free survival plotting
high versus low expression of CXCR4 is shown in Fig. 1.
High expression of CXCR4 retained its strength as
independent predictor of decreased prognosis in disease
free survival (HR: 2.0, p=0.03; Table 1). Also, TNM stage
(HR: 2.9, p=0.001; HR: 3.1, p=0.001) retained its strength
as independent predictors for disease free and overall
survival, while patient age (HR: 2.0, p<0.05) was found
to be an independent predictor only for overall survival.
Our RT-PCR results showed that high expression of
CXCR4 is independently associated with poor disease free
survival for colorectal cancer patients.
Nuclear Localization of CXCR4 Determines Prognosis
for Colorectal Cancer Patients
Using immunohistochemistry a TMA of 58 colorectal
tumors was stained for CXCR4. We observed immunore-
activity for CXCR4 in the cytoplasm, cell membrane and
nucleus of normal and tumor intestinal epithelial cells
(Fig. 2). For prognostic purpose only CXCR4 expression in
the cancer epithelium was scored. Cytoplasmic staining and
nuclear staining were semi-quantitative analyzed, according
to previous publications [20]. For cytoplasmic CXCR4
staining 22 (38%) tumors were classified as weak and 36 as
strong (62%). For nuclear CXCR4 staining 15 tumors were
classified as low (26%) and 43 were strong (74%). No
correlation was found between nuclear and cytoplasmic
expression of CXCR4. Also no correlation was found
between level of CXCR4 mRNA and either nuclear or
cytoplasmic expression of CXCR4 as determined by
immunohistochemical techniques. Association of cytoplas-
mic CXCR4 expression to clinicopathological and survival
parameters did not reveal any significant correlation. In
contrast to cytoplasmic localized CXCR4, nuclear localized
CXCR4 was found to be a significant predictor for survival.
Using univariate cox regression analyses, we showed that
strong expression of CXCR4 was significantly (p=0.03)
associated with decreased overall survival compared to
patients with weak nuclear expression of CXCR4. Patient
characteristics and several markers that have an effect on
disease free survival and overall survival in colorectal
cancer showed no significant association with level of
CXCR4 (Table 2). In addition, patient age (p=0.008, p=
0.006) and TNM stage (p=0.002, p=0.002) were found to
be significant predictors for disease free survival and
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iate analysis, strong expression of CXCR4 (HR: 2.6, p=
0.04; HR: 3.7, p=0.02) retained its strength as independent
predictor for both poor disease free survival and overall
survival, together with TNM stage (HR: 2.9, p=0.003; HR:
3.3, p=0.002) and median age (HR: 2.5, p=0.01; HR: 2.8,
p=0.008; Table 2). Semi-quantitative analysis of immuno-
histochemical staining associated to survival showed that
strong nuclear localization was associated with poor
prognosis for colorectal cancer patients.
Discussion
The expression of CXCR4 has been detected in a large
number of different types of cancers, together with its use
as prognostic biomarker [3, 27]. In the present study we
evaluated the expression of CXCR4 in colorectal cancer by
quantitative RT-PCR and immunohistochemical staining.
Strong expression of nuclear localized CXCR4 and high















p-value HR (95% CI) p-value p-value HR (95% CI) p-value
Gender
Male (%) 19 (54%) 16 (46%) 0.48 0.8 1.0
Female (%) 16 (46%) 19 (54%)
Location tumor
Proximal (%) 18 (51%) 18 (51%) 1 0.5 0.5
Distal (%) 17 (49%) 17 (49%)
Median age at diagnosis (years)
<68.5 15 (43%) 20 (57%) 0.2 0.006 1.8 0.06 0.005 2.0 <0.05
>68.5 20 (57%) 15 (43%) 1.0–3.5 (1.0–3.9)
TNM stage
I and II 24 (69%) 23 (66%) 0.8 <0.001 2.9 0.001 <0.001 3.1 0.001
III 11 (31%) 12 (34%) (1.6–5.5) (1.6–6.0)
Pathway
MSI 29 (83%) 29 (83%) 1 0.6 0.5
MSS 6 (17%) 6 (17%)
CXCR4
High 0.006 2.0 0.03 0.01 1.8 0.07
Low (1.1–3.7) (1.0–3.6)
Clinicopathological characteristics and survival results of patients with high and low RNA level of CXCR4. Level of CXCR4 was determined in
an independent panel colorectal cancer patients. The table displays data of the cohort, as described in materials and methods, using quantitative
RT-PCR to determine the level of CXCR4. The 50th percentile was used to define high versus low expression of CXCR4. On the left side of the
table the distribution of high versus low expression of CXCR4 with respect to clinical and pathological characteristics and the relation of CXCR4
to clinicopathological factors are displayed. On the right side of the table, prognostic factors are displayed. Univariate Cox regression analyses
were performed to identify prognostic factors for disease free and overall survival. All factors with a p value ≤ 0.10 were subjected to Multivariate
Cox regression analysis. Numbers (N) of patients are indicated with percentages shown in parentheses
MSS microsatellite stable; MSI microsatellite instable; HR Hazard Ratio; CI Confidence Interval




Fig. 1 Correlation between disease free survival and expression of
CXCR4 assessed by RT-PCR in a cohort of colorectal cancer patients.
Kaplan Meier survival curve is displayed. Patients with low
expression of CXCR4 had a significant (p=0.006) increased disease
free survival compared to patients with high expression of CXCR4
4 F.M. Speetjens et al.Fig. 2 Examples of CXCR4 immunohistochemical staining of human
colorectal tumors. a displays an example of weak cytoplasmic staining
in combination with strong staining of the nucleoplasm. b displays an
example of intermediate cytoplasmic staining in combination with
weak nuclear staining for CXCR4. c displays an example of strong
cytoplasmic intensity of CXCR4 while of the nucleus only the
envelope is stained and the nucleoplasm is not stained; original
magnification ×400















p-value HR (95% CI) p-value p-value HR (95% CI) p-value
Gender
Male (%) 21 (49%) 7 (47%) 0.9 0.8 0.9
Female (%) 22 (51%) 8 (53%)
Location tumor
Proximal (%) 21 (49%) 10 (67%) 0.2 0.6 0.7
Distal (%) 22 (51%) 5 (33%)
Median age at diagnosis (years)
<69.7 21 (49%) 8 (53%) 0.8 0.008 2.5 0.01 0.006 2.8 0.008
>69.7 22 (51%) 7 (47%) (1.2–4.9) (1.3–5.8)
TNM stage
I and II 28 (65%) 11 (73%) 0.6 0.002 2.9 0.003 0.002 3.3 0.002
III 15 (35%) 4 (27%) (1.4–5.8) (1.5–6.8)
Pathway
MSI 7 (16%) 5 (33%) 0.2 0.7 0.6
MSS 36 (84%) 10 (67%)
CXCR4
Strong 0.07 2.6 0.04 0.03 3.7 0.02
Weak (1.0–6.2) (1.35–11)
Clinicopathological characteristics and survival results of patients with high and low nuclear protein expression of CXCR4. Level of CXCR4 was
determined in an independent panel colorectal cancer patients. The table displays the results after immunohistochemical staining and semi-
quantitative analyses of nuclear expression of CXCR4 in tumor cells, as described in materials and methods. For nuclear CXCR4 staining, 15
tumors were classified as low (26%) and 43 were strong (74%). On the left side of the table the distribution of high versus low expression of
CXCR4 with respect to clinical and pathological characteristics and the relation of CXCR4 to clinicopathological factors are displayed. On the
right side of the table, prognostic factors are displayed. Univariate Cox regression analyses were performed to identify prognostic factors for
disease free and overall survival. All factors with a p value ≤ 0.10 were subjected to Multivariate Cox regression analysis. Numbers (N) of patients
are indicated with percentages shown in parentheses
MSS microsatellite stable; MSI microsatellite instable; HR Hazard Ratio; CI Confidence Interval
aStatistical significant p-values are in bold
Nuclear localization of CXCR4 determines prognosis 5RNA levels of CXCR4 were both independent significant
predictors for poor overall and disease free survival. Our
results were consistent with others’ recent RT-PCR data
[10, 15].
We found no correlation between expression of CXCR4
mRNA (RT-PCR) and nuclear CXCR4 expression (immu-
nohistochemistry). This might be explained that level of
CXCR4 mRNA does not distinct between levels of
membrane expressed CXCR4 protein and nuclear expressed
CXCR4. Also does RNA isolated from tumor samples,
includes RNA from cells other than tumor cells, for
instance tumor infiltrated T cells. Tumor infiltrated T cells
also express CXCR4 [28, 29] and presence is positively
associated with prognosis of colorectal cancer patients [20–
23]. As a result tumor infiltrated T cells might disturb
prognostic evaluation of CXCR4 mRNA expression isolat-
ed from tumor tissues by quantitative RT-PCR. Therefore
we additionally used immunohistochemical techniques to
semi-quantitatively assess expression of CXCR4 in tumor
cells only. Although RT-PCR is a better technique to
quantify level of expression, the use of immunohistochem-
ical techniques for clinical and prognostic purposes is
preferred above RT-PCR, since the intratumoral and
intracellular distribution of CXCR4 can be determined
which is not possible using RT-PCR. For prognostic
purposes we showed that only nuclear localization of
CXCR4 was independently predictive for prognosis of
colorectal cancer patients in contrast to expression in the
cytoplasm. Using immunohistochemical staining to semi-
quantitatively score nuclear and cytoplasmic expression of
CXCR4 and associating results to survival parameters, has
been done in various types of tumors amongst others in a
large panel of breast carcinomata [20–23]. To our knowl-
edge, only two studies determined the association between
colorectal cancer and prognosis, using immunohistochem-
ical techniques [13, 15]. These studies only detected
cytoplasmic and sometimes membrane staining, while no
nuclear staining was separately investigated in both studies.
We observed expression of CXCR4 both in the cytoplasm
and nucleus of colorectal cancer tissue and though rarely,
membrane expression. Our study is the first that was able to
distinguish nuclear from cytoplasmic CXCR4 expression in
colorectal cancer. A possible explanation for this fact might
be that we used a different antibody compared with
previous studies.
Shim et al. showed in cultured cells that CXCL12 ligand
binding to CXCR4 induced translocation of CXCR4 to the
cytoplasm and to the nucleus of cells [30]. The transloca-
tion of CXCR4 to the nucleus might be involved in
biological processes and function as a transcription factor
as has been described for other receptors, for instance the
epidermal growth factor receptor (EGFR) [30, 31]. Recent-
ly for lung tumors it has been shown that CXCL12
activates CXCR4 receptor and ERK pathway, which in
turn induces IKKa/b phosphorylation, p65 Ser536 phos-
phorylation, and NF-kB activation, which leads to b1 and
b3 integrins expression and increases the migration of
human lung cancer cells [32]. Since our data imply that
especially nuclear staining predicts prognosis, additional
research should provide insight in the nuclear function of
CXCR4 in colorectal cancer. Moreover if CXCR4 is a
transcription or has another specific function in the nucleus
it is important to learn which genes are activated or
inhibited by CXCR4 in colorectal cancer cells.
Currently, only the TNM staging is used to stage patients
with colorectal cancer. Adjuvant treatment is based on this
staging. Combining TNM staging with selected biomarkers
might better define patients who are at risk for metastases
or recurrences and might define patients who would benefit
from adjuvant treatment. In conclusion, our data showed
that especially nuclear localized CXCR4 determines prog-
nosis for colorectal patients. The use of CXCR4 might
improve the current staging of colorectal cancer patients.
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